Literature DB >> 21880583

Predictors of clinical virulence in community-onset methicillin-resistant Staphylococcus aureus infections: the importance of USA300 and pneumonia.

Bala Hota1, Rosie Lyles, Jean Rim, Kyle J Popovich, Thomas Rice, Alla Aroutcheva, Robert A Weinstein.   

Abstract

BACKGROUND: Though USA300 community-onset methicillin-resistant Staphylococcus aureus (CO-MRSA) has emerged as a major public health concern in the United States, its relative virulence is unknown. We sought to evaluate if the USA300 strain of CO-MRSA causes more severe infections than other MRSA (ie, USA100, -500, -800, and others) strains.
METHODS: An epidemiologic study was conducted from 2000 to 2007 to measure rates of severe infection. A matched case-control study was conducted from 2004 to 2006 to assess the relationship of strain type, syndrome, and severity of infection. Severe illness was defined as CO-MRSA infections with medical intensive care unit (MICU) admission or death within 1 week of admission. Controls were those with CO-MRSA infection without MICU admission.
RESULTS: We found an incidence of 75 cases per 100000 people of CO-MRSA infection in 2000, which increased to a rate of 396 per 100000 in 2007 (relative risk [RR], 5.3; 95% confidence interval [CI], 4.47-6.27). The incidence of severe infections increased from 5 cases per 100000 in 2000 to 17 per 100000 in 2007 (RR, 3.4; 95% CI; 1.67-6.43). USA300 strains were negatively associated with severe clinical courses or death as compared with other MRSA strain types. The highest risk of severe infection was found in those with pulmonary embolic infiltrates and bacteremia in the setting of USA300 infection (odds ratio, 31.41; 95% CI, 6.40-154.23).
CONCLUSIONS: Our findings suggest that USA300 infections are negatively associated with severe clinical courses, suggesting less virulence than other MRSA strains, except in the setting of pneumonia with septic pulmonary emboli.

Entities:  

Mesh:

Year:  2011        PMID: 21880583     DOI: 10.1093/cid/cir472

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  24 in total

1.  Analysis of pathogen and host factors related to clinical outcomes in patients with hospital-acquired pneumonia due to methicillin-resistant Staphylococcus aureus.

Authors:  Nadia Z Haque; Samia Arshad; Paula Peyrani; Kimbal D Ford; Mary B Perri; Gordon Jacobsen; Katherine Reyes; Ernesto G Scerpella; Julio A Ramirez; Marcus J Zervos
Journal:  J Clin Microbiol       Date:  2012-02-15       Impact factor: 5.948

Review 2.  Virulence strategies of the dominant USA300 lineage of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA).

Authors:  Lance R Thurlow; Gauri S Joshi; Anthony R Richardson
Journal:  FEMS Immunol Med Microbiol       Date:  2012-03-05

3.  Predictors of hospitals with endemic community-associated methicillin-resistant Staphylococcus aureus.

Authors:  Courtney R Murphy; Lyndsey O Hudson; Brian G Spratt; Kristen Elkins; Leah Terpstra; Adrijana Gombosev; Christopher Nguyen; Paul Hannah; Richard Alexander; Mark C Enright; Susan S Huang
Journal:  Infect Control Hosp Epidemiol       Date:  2013-04-22       Impact factor: 3.254

Review 4.  Community-associated methicillin-resistant Staphylococcus aureus infection: Literature review and clinical update.

Authors:  Kassandra Loewen; Yoko Schreiber; Mike Kirlew; Natalie Bocking; Len Kelly
Journal:  Can Fam Physician       Date:  2017-07       Impact factor: 3.275

5.  Effects of Tedizolid Phosphate on Survival Outcomes and Suppression of Production of Staphylococcal Toxins in a Rabbit Model of Methicillin-Resistant Staphylococcus aureus Necrotizing Pneumonia.

Authors:  Vien T M Le; Hoan N Le; Marcos Gabriel Pinheiro; Kenneth J Hahn; Mary L Dinh; Kajal B Larson; Shawn D Flanagan; Cedric Badiou; Gerard Lina; Christine Tkaczyk; Bret R Sellman; Binh An Diep
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

6.  Costs of healthcare- and community-associated infections with antimicrobial-resistant versus antimicrobial-susceptible organisms.

Authors:  Matthew J Neidell; Bevin Cohen; Yoko Furuya; Jennifer Hill; Christie Y Jeon; Sherry Glied; Elaine L Larson
Journal:  Clin Infect Dis       Date:  2012-06-14       Impact factor: 9.079

7.  Predicting methicillin resistance among community-onset Staphylococcus aureus bacteremia patients with prior healthcare-associated exposure.

Authors:  S-Y Chen; W-C Chiang; M H-M Ma; P-R Hsueh; S-C Chang; C-C Fang; S-C Chen; W-J Chen; W-C Chie; M-S Lai
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-05-19       Impact factor: 3.267

8.  Reduction of methicillin-resistant Staphylococcus aureus infection among veterans in Atlanta.

Authors:  Edward Stenehjem; Cortney Stafford; David Rimland
Journal:  Infect Control Hosp Epidemiol       Date:  2012-11-14       Impact factor: 3.254

9.  Comparative pharmacodynamics of the new oxazolidinone tedizolid phosphate and linezolid in a neutropenic murine Staphylococcus aureus pneumonia model.

Authors:  Alexander J Lepak; Karen Marchillo; Solen Pichereau; William A Craig; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2012-09-10       Impact factor: 5.191

10.  A comparison of clinical outcomes between healthcare-associated infections due to community-associated methicillin-resistant Staphylococcus aureus strains and healthcare-associated methicillin-resistant S. aureus strains.

Authors:  S J Eells; J A McKinnell; A A Wang; N L Green; D Whang; P O'Hara; M L Brown; L G Miller
Journal:  Epidemiol Infect       Date:  2012-12-06       Impact factor: 2.451

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.